News Illumina says Icahn’s board candidates “do not add value” Icahn's board picks "will damage Illumina’s core business," says the gene sequencing company.
News Concentra gatecrashes Jounce and Redx’ merger party Biotech interloper is led by Kevin Tang of Tang Capital management, which owns 10% of Jounce.
News Rumour of Pfizer, Seagen deal is true, with $43bn price tag Pfizer says Seagen's current and future drugs could add $10 billion to its revenues from 2030.
News Sanofi buys Provention and diabetes drug Tzield for $2.9bn T1D prevention drug has been tipped as a blockbuster, boosting Sanofi's diabetes franchise.
News Carl Icahn planning proxy fight at Illumina; report Activist investor claims takeover of liquid biopsy firm Grail points to "reckless" management.
News Forget Merck, now Pfizer is said to be after Seagen Rumour of negotiations comes as Pfizer is facing a steep patent cliff in the next few years.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
